CP-25, a novel anti-inflammatory and immunomodulatory drug, inhibits the functions of activated human B cells through regulating BAFF and TNF-alpha signaling and comparative efficacy with biological agents

Feng Zhang, Jin Ling Shu, Ying Li, Yu Jing Wu, Xian Zheng Zhang, Le Han, Xiao Yu Tang, Chen Wang, Qingtong Wang, Jing Yu Chen, Yan Chang, Hua Xun Wu, Ling Ling Zhang, Wei Wei

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Paeoniflorin-6'-O-benzene sulfonate (code: CP-25) was the chemistry structural modifications of Paeoniflorin (Pae). CP-25 inhibited B cells proliferation stimulated by B cell activating factor belonging to the TNF family (BAFF) or Tumor necrosis factor alpha (TNF-alpha). CP-25, Rituximab and Etanercept reduced the percentage and numbers of CD19+ B cells, CD19+CD20+ B cells, CD19+CD27+ B cells and CD19+CD20+CD27+ B cells induced by BAFF or TNF-alpha. There was significant difference between CP-25 and Rituximab or CP-25 and Etanercept. CP-25 down-regulated the high expression of BAFFR, BCMA, and TACI stimulated by BAFF or TNF-alpha. The effects of Rituximab and Etanercept on BAFFR or BCMA were stronger than that of CP-25. CP-25, Rituximab and Etanercept down-regulated significantly the expression of TNFR1 and TNFR2 on B cell stimulated by BAFF or TNF-alpha. CP-25, Rituximab and Etanercept down-regulated the expression of MKK3, P-p38, P-p65, TRAF2, and p52 in B cells stimulated by BAFF and the expression of TRAF2 and P-p65 in B cells stimulated by TNF-alpha. These results suggest that CP-25 regulated moderately activated B cells function by regulating the classical and alternative NF-κB signaling pathway mediated by BAFF and TNF-alpha-TRAF2-NF-κB signaling pathway. This study suggests that CP-25 may be a promising anti-inflammatory immune and soft regulation drug.

Original languageEnglish (US)
Article number933
JournalFrontiers in Pharmacology
Volume8
Issue numberDEC
DOIs
StatePublished - Dec 22 2017
Externally publishedYes

Fingerprint

Biological Factors
B-Lymphocytes
Anti-Inflammatory Agents
Tumor Necrosis Factor-alpha
TNF Receptor-Associated Factor 2
Pharmaceutical Preparations
B-Cell Activating Factor
Receptors, Tumor Necrosis Factor, Type II
Receptors, Tumor Necrosis Factor, Type I
Drug and Narcotic Control
Cell Proliferation
Etanercept
Rituximab

Keywords

  • BAFF
  • CP-25
  • Etanercept
  • Rituximab
  • Signaling pathway
  • TNF-alpha

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

CP-25, a novel anti-inflammatory and immunomodulatory drug, inhibits the functions of activated human B cells through regulating BAFF and TNF-alpha signaling and comparative efficacy with biological agents. / Zhang, Feng; Shu, Jin Ling; Li, Ying; Wu, Yu Jing; Zhang, Xian Zheng; Han, Le; Tang, Xiao Yu; Wang, Chen; Wang, Qingtong; Chen, Jing Yu; Chang, Yan; Wu, Hua Xun; Zhang, Ling Ling; Wei, Wei.

In: Frontiers in Pharmacology, Vol. 8, No. DEC, 933, 22.12.2017.

Research output: Contribution to journalArticle

Zhang, Feng ; Shu, Jin Ling ; Li, Ying ; Wu, Yu Jing ; Zhang, Xian Zheng ; Han, Le ; Tang, Xiao Yu ; Wang, Chen ; Wang, Qingtong ; Chen, Jing Yu ; Chang, Yan ; Wu, Hua Xun ; Zhang, Ling Ling ; Wei, Wei. / CP-25, a novel anti-inflammatory and immunomodulatory drug, inhibits the functions of activated human B cells through regulating BAFF and TNF-alpha signaling and comparative efficacy with biological agents. In: Frontiers in Pharmacology. 2017 ; Vol. 8, No. DEC.
@article{f476edd42b5a4fe4970bd7ad5b28f73c,
title = "CP-25, a novel anti-inflammatory and immunomodulatory drug, inhibits the functions of activated human B cells through regulating BAFF and TNF-alpha signaling and comparative efficacy with biological agents",
abstract = "Paeoniflorin-6'-O-benzene sulfonate (code: CP-25) was the chemistry structural modifications of Paeoniflorin (Pae). CP-25 inhibited B cells proliferation stimulated by B cell activating factor belonging to the TNF family (BAFF) or Tumor necrosis factor alpha (TNF-alpha). CP-25, Rituximab and Etanercept reduced the percentage and numbers of CD19+ B cells, CD19+CD20+ B cells, CD19+CD27+ B cells and CD19+CD20+CD27+ B cells induced by BAFF or TNF-alpha. There was significant difference between CP-25 and Rituximab or CP-25 and Etanercept. CP-25 down-regulated the high expression of BAFFR, BCMA, and TACI stimulated by BAFF or TNF-alpha. The effects of Rituximab and Etanercept on BAFFR or BCMA were stronger than that of CP-25. CP-25, Rituximab and Etanercept down-regulated significantly the expression of TNFR1 and TNFR2 on B cell stimulated by BAFF or TNF-alpha. CP-25, Rituximab and Etanercept down-regulated the expression of MKK3, P-p38, P-p65, TRAF2, and p52 in B cells stimulated by BAFF and the expression of TRAF2 and P-p65 in B cells stimulated by TNF-alpha. These results suggest that CP-25 regulated moderately activated B cells function by regulating the classical and alternative NF-κB signaling pathway mediated by BAFF and TNF-alpha-TRAF2-NF-κB signaling pathway. This study suggests that CP-25 may be a promising anti-inflammatory immune and soft regulation drug.",
keywords = "BAFF, CP-25, Etanercept, Rituximab, Signaling pathway, TNF-alpha",
author = "Feng Zhang and Shu, {Jin Ling} and Ying Li and Wu, {Yu Jing} and Zhang, {Xian Zheng} and Le Han and Tang, {Xiao Yu} and Chen Wang and Qingtong Wang and Chen, {Jing Yu} and Yan Chang and Wu, {Hua Xun} and Zhang, {Ling Ling} and Wei Wei",
year = "2017",
month = "12",
day = "22",
doi = "10.3389/fphar.2017.00933",
language = "English (US)",
volume = "8",
journal = "Frontiers in Pharmacology",
issn = "1663-9812",
publisher = "Frontiers Media S. A.",
number = "DEC",

}

TY - JOUR

T1 - CP-25, a novel anti-inflammatory and immunomodulatory drug, inhibits the functions of activated human B cells through regulating BAFF and TNF-alpha signaling and comparative efficacy with biological agents

AU - Zhang, Feng

AU - Shu, Jin Ling

AU - Li, Ying

AU - Wu, Yu Jing

AU - Zhang, Xian Zheng

AU - Han, Le

AU - Tang, Xiao Yu

AU - Wang, Chen

AU - Wang, Qingtong

AU - Chen, Jing Yu

AU - Chang, Yan

AU - Wu, Hua Xun

AU - Zhang, Ling Ling

AU - Wei, Wei

PY - 2017/12/22

Y1 - 2017/12/22

N2 - Paeoniflorin-6'-O-benzene sulfonate (code: CP-25) was the chemistry structural modifications of Paeoniflorin (Pae). CP-25 inhibited B cells proliferation stimulated by B cell activating factor belonging to the TNF family (BAFF) or Tumor necrosis factor alpha (TNF-alpha). CP-25, Rituximab and Etanercept reduced the percentage and numbers of CD19+ B cells, CD19+CD20+ B cells, CD19+CD27+ B cells and CD19+CD20+CD27+ B cells induced by BAFF or TNF-alpha. There was significant difference between CP-25 and Rituximab or CP-25 and Etanercept. CP-25 down-regulated the high expression of BAFFR, BCMA, and TACI stimulated by BAFF or TNF-alpha. The effects of Rituximab and Etanercept on BAFFR or BCMA were stronger than that of CP-25. CP-25, Rituximab and Etanercept down-regulated significantly the expression of TNFR1 and TNFR2 on B cell stimulated by BAFF or TNF-alpha. CP-25, Rituximab and Etanercept down-regulated the expression of MKK3, P-p38, P-p65, TRAF2, and p52 in B cells stimulated by BAFF and the expression of TRAF2 and P-p65 in B cells stimulated by TNF-alpha. These results suggest that CP-25 regulated moderately activated B cells function by regulating the classical and alternative NF-κB signaling pathway mediated by BAFF and TNF-alpha-TRAF2-NF-κB signaling pathway. This study suggests that CP-25 may be a promising anti-inflammatory immune and soft regulation drug.

AB - Paeoniflorin-6'-O-benzene sulfonate (code: CP-25) was the chemistry structural modifications of Paeoniflorin (Pae). CP-25 inhibited B cells proliferation stimulated by B cell activating factor belonging to the TNF family (BAFF) or Tumor necrosis factor alpha (TNF-alpha). CP-25, Rituximab and Etanercept reduced the percentage and numbers of CD19+ B cells, CD19+CD20+ B cells, CD19+CD27+ B cells and CD19+CD20+CD27+ B cells induced by BAFF or TNF-alpha. There was significant difference between CP-25 and Rituximab or CP-25 and Etanercept. CP-25 down-regulated the high expression of BAFFR, BCMA, and TACI stimulated by BAFF or TNF-alpha. The effects of Rituximab and Etanercept on BAFFR or BCMA were stronger than that of CP-25. CP-25, Rituximab and Etanercept down-regulated significantly the expression of TNFR1 and TNFR2 on B cell stimulated by BAFF or TNF-alpha. CP-25, Rituximab and Etanercept down-regulated the expression of MKK3, P-p38, P-p65, TRAF2, and p52 in B cells stimulated by BAFF and the expression of TRAF2 and P-p65 in B cells stimulated by TNF-alpha. These results suggest that CP-25 regulated moderately activated B cells function by regulating the classical and alternative NF-κB signaling pathway mediated by BAFF and TNF-alpha-TRAF2-NF-κB signaling pathway. This study suggests that CP-25 may be a promising anti-inflammatory immune and soft regulation drug.

KW - BAFF

KW - CP-25

KW - Etanercept

KW - Rituximab

KW - Signaling pathway

KW - TNF-alpha

UR - http://www.scopus.com/inward/record.url?scp=85039041057&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85039041057&partnerID=8YFLogxK

U2 - 10.3389/fphar.2017.00933

DO - 10.3389/fphar.2017.00933

M3 - Article

AN - SCOPUS:85039041057

VL - 8

JO - Frontiers in Pharmacology

JF - Frontiers in Pharmacology

SN - 1663-9812

IS - DEC

M1 - 933

ER -